Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 Australian Biotech
Latest Video
New Stories
-
Just in case they didn't get the message, Mark Butler has reminded them of the Government's view
July 7, 2026 - - Latest News -
Australian Healthcare Associates retains deal to administer the CSO funding pool through 2029
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News -
Brandon Capital secures landmark Novartis acquisition of Myricx Bio
July 6, 2026 - - Latest News -
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech

